Federated Hermes Inc. Acquires 54,751 Shares of Humana Inc. (NYSE:HUM)

Federated Hermes Inc. lifted its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 231.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 78,357 shares of the insurance provider's stock after purchasing an additional 54,751 shares during the quarter. Federated Hermes Inc. owned approximately 0.07% of Humana worth $19,880,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after buying an additional 1,751,857 shares in the last quarter. Norges Bank bought a new position in Humana during the fourth quarter worth about $416,202,000. Pzena Investment Management LLC boosted its holdings in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after purchasing an additional 1,103,132 shares in the last quarter. Boston Partners raised its holdings in shares of Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock worth $279,236,000 after buying an additional 893,637 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its position in shares of Humana by 83.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 673,715 shares of the insurance provider's stock worth $170,928,000 after buying an additional 306,433 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Humana Stock Down 3.2 %

Shares of Humana stock traded down $9.50 on Monday, hitting $285.54. The company had a trading volume of 362,478 shares, compared to its average volume of 1,746,919. The stock has a 50-day moving average of $265.55 and a 200-day moving average of $270.35. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The firm has a market capitalization of $34.46 billion, a P/E ratio of 28.70, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio is presently 35.58%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HUM. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Truist Financial raised their price target on Humana from $290.00 to $325.00 and gave the company a "hold" rating in a report on Friday. Mizuho boosted their price objective on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Finally, Guggenheim assumed coverage on Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target for the company. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $288.60.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.